Delving into the Latest Updates on Xindu Pty Ltd with Synapse

概览

疾病领域	数量

免疫系统疾病	1

排名前五的药物类型	数量

间充质干细胞疗法	1

关联

1

项与 Xindu Pty Ltd 相关的药物

XSTEM

靶点-

作用机制-

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

1

项与 Xindu Pty Ltd 相关的临床试验

NCT05344157

/ Active, not recruiting临床1/2期

A First-in-Human Open-Label Phase 1/2a Study to Evaluate Safety, Tolerability and Efficacy of a Single Intra-Articular Injection of Allogeneic Mesenchymal Stem Cells Selected for Integrin α10β1 (XSTEM-OA) in Adult Patients With Symptomatic Knee Osteoarthritis

The aim of the study is to assess safety, tolerability and preliminary efficacy of XSTEM-OA when administered as a single intra-articular injection to patients with symptomatic knee osteoarthritis. The study is divided into two parts; a dose escalation (Part A) and an optional dose expansion part (Part: B). Three dose levels are planned to be evaluated in Part A and selected dose level(s) may be further expanded in Part B.

开始日期2022-06-22

申办/合作机构

Xindu Pty Ltd

[+1]

100 项与 Xindu Pty Ltd 相关的临床结果

登录后查看更多信息

0 项与 Xindu Pty Ltd 相关的专利（医药）

登录后查看更多信息

100 项与 Xindu Pty Ltd 相关的药物交易

登录后查看更多信息

100 项与 Xindu Pty Ltd 相关的转化医学

登录后查看更多信息